Michael Liang, PhD
Michael Liang is a partner at Baird Capital. He joined Baird Capital’s Venture Capital team in 2006 and concentrates on healthcare investments, focusing across investments in medical devices, life science tools, diagnostics, and healthcare services and healthcare IT. Prior to joining Baird Capital, Mike was a venture investor with Advent Venture Partners and before that, served in an operating role as a Director of R&D at Cortek, Inc., a spinal orthopedics company. Mike is currently a member of the board of directors of GenomeDx Biosciences, Palyon Medical, PathCentral, Inc., Veniti, Inc., and Zurex Pharma. He was previously a board member of Interlace Medical before its acquisition in 2011. Mike received a BS from the University of California, Berkeley, a PhD in biophysical chemistry from Stanford University and conducted a postdoctoral fellowship at Harvard University.
Michael Albin, PhD
Michael Albin is a consultant in life sciences and diagnostics providing strategic assessment and advice for companies, diligence on investments and M&A, and guidance for early-stage entities over the past eleven years. He was Vice President, of Strategic Technologies at Applera Corp. and VP of Science and Technology for Applied Biosystems, having increased responsibility for R&D plans, new technology development and business development during his fourteen years with the Company. He earned his BS in chemistry from Polytechnic Institute, Brooklyn, NY and his PhD in chemistry from Pennsylvania State University. He completed his postdoctoral studies at the California Institute of Technology. Dr. Albin has served on a number of boards of start-up companies, industrial advisory boards of universities, and reviewer for US and Canada granting agencies.
George Rehm, JD
George Rehm is a managing partner of aeris CAPITAL AG in Switzerland. He joined Aeris in 2000 and has over thirty years of experience as a lawyer and executive in international licensing, technology transfer and investment and privatization transactions in the US, Europe and Asia. He holds board seats at Crescendo Biosciences, Adamas Pharmaceuticals, Jiff Inc. Tethys Bioscience, Sensovation AG, and TTTech AG. Prior to joining aeris in 2000, Mr. Rehm worked as legal counsel for numerous international technology transfer transactions and served as chief European consultant to Bristol-Myers Squibb on an oncology care project, which involved delivery of services through ambulatory clinics throughout the EU. Mr. Rehm remains as counsel in the law firm Weitnauer Partners. He received his BSFS from Georgetown University, and a JD from the University of California, Hastings College of Law graduate studies in City Planning at the College of Environmental Design, UC Berkeley and served as graduate assistant at the Earl Warren Legal Institute, UC Berkeley, Boalt Hall. Mr. Rehm has written and lectured frequently in Germany and the US on international trade, investment, technology transfer, health care, and venture capital.
Brian Cooper co-founded Retalix, a provider of integrated software solutions for high volume, high complexity consumer goods retailers and distributors that was acquired by NCR Corporation in 2012. He served as Retalix chief financial officer until 1999 and as a board member until 2010. Brian serves on the board of directors of YCD Multimedia Ltd., Regenecure Ltd. and Exonoid Medical Devices Ltd. Brian also serves as an officer specializing in economics and programming in the Isareli Defense Forces and holds a BA in economics from Haifa University.